Based on the findings of the HARMONI-A study, the National Medical Products Administration (NMPA) approved ivonescimab, combined with chemotherapy, for the treatment of EGFR-mutated locally advanced or metastatic non-squamous NSCLC patients who have progressed after treatment with EGFR-TKIs, in May 2024 (9, 10). This evidence concerns the gene EGFR and non-small cell lung carcinoma.